Children's Oncology Group AAML1831 phase III clinical trial experimental design schema (NCT04293562). AE, cytarabine/etoposide; Allo, allogeneic; AR, allelic ratio; DA, daunomycin/cytarabine; DL, dose level; Gilt, gilteritinib; GO, gemtuzumab ozogamicin; HDAC, high-dose cytarabine/asparaginase (Capizzi II regimen); HSCT, hematopoietic stem cell transplantation; Ind, induction; Int, intensification; ITD, internal tandem duplication; MA, mitoxantrone/cytarabine; Maint, maintenance.